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Time for Correct Diagnosis and Categorisation of Heart Failure in Primary Care 
Heart failure (HF) affects approximately 900,000 people in the UK and is a leading cause of 
hospitalisation, accounting for 5% of emergency admissions (1).  Correct identification of patients 
with HF holds promise for ensuring that patients receive appropriate intervention and management.  
However, there is good evidence that this is problematic in two respects: firstly with respect to 
correct diagnosis of the presence or absence of HF; and secondly with respect to correct 
categorisation of the type of HF, if HF is indeed present. 
Diagnosis of the Presence or Absence of HF 
Studies have documented under-diagnosis of HF, especially among older patients presenting with 
dyspnoea (2).  However, others have documented over-diagnosis: an audit of 10 practices in 
Northwest England found that 18% of diagnoses were inappropriate and that 22% needed further 
evaluation (3).   In this month’s journal, Valk et al (4) report similar findings from a Dutch expert 
panel review of available diagnostic information for 683 patients with a GP diagnosis of HF. Whilst 
63.5% of patients coded as having HF were found to have definite HF, the diagnosis was determined 
only to be ‘possible’ in 19.2% and ‘absent’ in 17.3%.   
The diagnostic pathway for non-acute HF in UK primary care recommends measurement of 
natriuretic peptides for patients with signs and symptoms suggestive of heart failure without 
previous myocardial infarction, and referral for echocardiography based on results (1).  Since 2006, 
confirmation of HF by echocardiography or specialist assessment has been incentivised in the UK as 
a Quality and Outcomes Framework (QOF) indicator and is widely available through open access 
services.  Valk et al (4) found that amongst HF patients concluded to have HF, natriuretic peptide 
measurement or echocardiography had been performed in 97.5%, whilst amongst those with 
‘possible’ HF the rate was 74.8% and amongst those where HF was concluded to be absent, the rate 
was 83.9% 
It seems reasonable, therefore, to conclude that maximising the use of natriuretic peptide 
estimation and echocardiography according to current guidelines would help with the accurate 
diagnosis of the presence of HF. Whilst this is probably the case, there nevertheless remain further 
difficulties, even where echocardiography has been performed, in categorising the type of HF 
correctly.  
Categorisation of Type of HF  
The 434 patients in Valk, et al. (4) with confirmed HF were roughly divided 50:50 into HF with 
reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).  In studies 
documenting under-diagnosis of HF, the majority of patients (76%) with unrecognised HF were 
found to have HFpEF (2).  HFpEF is increasing by 10% per decade relative to HFrEF, primarily due to 
an ageing population living with chronic disease.   Risk factors for HFpEF include female sex, 
diabetes, higher BMI, smoking, hypertension, concentric left ventricular hypertrophy and atrial 
fibrillation (5).  Although there is heterogeneity, the most common phenotype of HFpEF is an elderly 
woman with hypertension and obesity (5).  Data from the United States demonstrate a trend toward 
increasing hospitalisation for patients with HFpEF and decreasing hospitalisation for HFrEF (6).  This 
analysis also found rehospitalisation rates to be 29% within 60-90 days for both groups of patients.   
Data from the UK National HF Audit 2009 – 2013 documented that all-cause mortality post 
hospitalisation was 38% for patients with HFrEF (median follow-up 433 days), and 44% for patients 
with HF with a higher ejection fraction (median follow-up 400 days) (7).  These morbidity and 
mortality data make a compelling case for correct categorisation as well as diagnosis, especially as 
treatment of HFrEF and HFpEF differ (see below). 
Presentation and Diagnosis of HFpEF 
Patients with HFpEF typically present with exercise intolerance and other signs and symptoms of 
heart failure.  Symptomatic patients with HFpEF may have increased natriuretic peptides, but the 
increase may be less than that seen in similar patients with HFrEF.  Echocardiographic findings for 
HFpEF are less easily interpreted.  Although diastolic dysfunction in HFpEF is observed by 
echocardiogram in two-thirds of affected patients at rest, some clinicians argue that assessment of 
diastolic function should be performed during exercise as this is more likely to achieve greater 
diagnostic accuracy.  The recent 2016 ESC HF guidelines now stipulate the following for diagnosis of 
HFpEF: clinical signs and symptoms of HF; preserved EF; elevated natriuretic peptides (in the non-
acute setting, BNP > 35 pg/mL or NT-proBNP > 125 pg/mL); and evidence of structural heart disease 
(left ventricular hypertrophy or left atrial enlargement) and/or diastolic dysfunction at rest or with 
exercise (8).  They characterise an EF > 50% as HFpEF, and an EF 40 – 49% as HF with a mid-range EF. 
Treatment of HFpEF: Why Correct Categorisation Matters 
None of the specific pharmacologic treatments used for HFrEF has been found to improve outcomes 
in patients with HFpEF (8).  Class I recommendations in the ESC guidelines are to control symptoms 
with diuretics and to manage comorbidities, including hypertension, since these appear to be drivers 
for the inflammation which lies at the root of the condition (8).  However, given patients’ age and 
likely duration of conditions, tight glycaemic control may not be warranted.  Greater understanding 
of the pathophysiology of HFpEF is helping to identify potential targets for pharmacological 
treatment, but these may require more precise patient phenotyping in order to identify specific 
groups of patients who can benefit. 
Non-pharmacological approaches hold promise.  A meta-analysis of randomised clinical trials of 
exercise training in patients with HFpEF (6 trials, 276 patients) found it was safe and effective in 
improving cardiorespiratory fitness and quality of life (9).  A small study of 100 patients with HFpEF 
(mean age 67, 80% women, mean BMI 39) found that those in the restricted calorie diet, exercise 
training, or diet + exercise arms showed improvement in fitness at 20 weeks compared to baseline 
and the control group.  Both diet and exercise resulted in weight loss and improvement in symptoms 
(10). 
Why is a Primary Care focus needed? 
Despite the expected prevalence of HFpEF among patients with heart failure in primary care, Read 
codes indicating HFpEF or diastolic heart failure are rarely used in general practice records.  Using a 
representative set of 300,000 adults aged over 18 in the Clinical Practice Research Database (CPRD), 
we found 1.26% prevalence of any one of the 5 Read codes for HFpEF or diastolic HF among patients 
coded for HF. This limited identification of patients with HFpEF in primary care is unsurprising, given 
the lack of QOF incentives specific to HFpEF and diagnostic difficulty.  Yet failure to identify and 
diagnose patients with HFpEF has implications both for patient care, and for costs to the health 
system, since evidence-based conventional treatment for HFrEF is largely ineffective in HFpEF. A 
primary care focus, leading to more accurate categorisation of patients with heart failure, would 
allow patients with HFpEF to receive treatment appropriate to their form of HF and avoid wasteful, 
ineffective use of treatment more suited to patients with HFrEF. It would also identify a cohort of 
patients with HFpEF who could be recruited into studies focused on improving their management 
and care. 
Cardiology services focus on patients with HFrEF, so in the UK the majority of patients with heart 
failure with preserved ejection fraction are managed in primary care.  Thus, the management of 
HFpEF is of major concern for primary care.  Patients with HF symptoms and/or signs should have 
their natriuretic peptides measured and where these are elevated, progress to echocardiography. 
Where this shows preserved EF with diastolic dysfunction or suggestive structural abnormalities and 
no other reason found for their symptoms, patients could be Read-coded for HFpEF from existing 
practice held data. Correct diagnosis of HF - especially of HFpEF - would allow its management 
against evolving evidence-based guidelines, avoid use of non-evidence-based HFrEF treatment and 
offer the possibility of research to improve outcomes for a HFpEF as a hitherto under-recognised 
condition. Patients can only benefit from maximising the accurate diagnosis and categorisation of 
HF.  Studies such as Valk, et al. (4) show that we still have work to do. 
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